medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 4

<< Back Next >>

Ann Hepatol 2011; 10 (4)

Liver cirrhosis and hepatocellular carcinoma in Mexico: impact of chronic infection by hepatitis viruses B and C

Torres-Poveda K, Burguete-García AI, Madrid-Marina V

Language: English
References: 29
Page: 556-558
PDF size: 35.22 Kb.


Text Extraction

Data on the prevalence of chronic liver disease (CLD) in Mexico, derived from selected series of hospitalized patients or from mortality registers, underestimate the prevalence of CLD. The etiology of liver disease is unknown in approximately 10% of patients with abnormal results on liver function tests. Cirrhosis is considered to be the most important risk factor for hepatocellular carcinoma (HCC). Several studies have indicated that 1-4% of all cirrhotic patients per year will develop HCC, according to the leading cause of the cirrhosis as reported by Méndez-Sánchez, et al. During 2006 the Ministry of Health in Mexico reported 122,170 (87.3%) avoidable deaths from liver cirrhosis between 2000 and 2004. Liver cirrhosis is the second cause of death in the 15- to 64-year-old age group; being three times higher in men than in women. The liver cirrhosis mortality in Mexico is substantially higher than in high-income countries.


REFERENCES

  1. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Avila F, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3(1): 30-3.

  2. Méndez-Sánchez N, Villa A, Vázquez-Elizondo G, Ponciano- Rodríguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol 2008; 7(3): 226-9.

  3. Secretaría de Salud. La mortalidad en México, 2000-2004. Muertes evitables: magnitud, distribución y tendencias. 2006. Available from: http://www.salud.gob.mx/apps/ htdocs/estadisticas/descargas/pdf/LaMortalidadEnMexico2000 2004.pdf

  4. Stevens G, Dias RH, Thomas KJ, Rivera JA, Carvalho N, Barquera S, Hill K, et al. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. PLoS Med 2008; 5(6): e125.

  5. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano- Rodríguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4(1): 52-5.

  6. Méndez-Sánchez N, García-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, Kobashi-Margáin RA, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9(4): 428-38.

  7. Narro-Robles J, Gutiérrrez-Ávila H, López-Cervantes M, Borges G, Rosovosky H. La mortalidad por cirrhosis hepatica en México I. Características epidemiológicas relevantes. Sal Púb Méx 1992; 34(4): 378-87.

  8. Bosetti C, Levi F, Luccini F, Zatonski WA, Negri E, La Vecchia C. Worlwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827-39.

  9. Velázquez R, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-7.

  10. Ruelas-Villavicencio AL, Vargas-Vorácková F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? Ann Hepatol 2004; 3(4): 152-9.

  11. Mondragón-Sánchez R, Ochoa-Carrillo FJ, Ruiz-Molina JM, Herrera-Goepfer R, Oñate-Ocaña LF, Aiello-Crocifoglio V. Hepatocellular carcinoma. Experience at the Instituto Nacional de Cancerología. Rev Gastroenterol Mex 1997; 62(1): 34-40 [Article in Spanish].

  12. Santos-López G, Sosa-Jurado F, Vallejo-Ruiz V, Meléndez- Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: A systematic review. J Infect 2008; 56(4): 281-90.

  13. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepúlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿un problema de salud pública emergente? Sal Púb Méx 2007; 49(Suppl. 3): S395, e403.

  14. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007; 50: 1-8.

  15. De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis 2011; 32(6): 787-95.

  16. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: A way out of the virus? World J Gastroenterol 2009; 15(40): 5016-9.

  17. Panduro A, Escobedo-Meléndez G, Fierro NA, Ruiz-Madrigal B, Zepeda-Carrillo EA, Román S. Epidemiology of viral hepatitis in Mexico. Sal Púb Méx 2011; 53(Supl. I): S37-S45.

  18. Burguete-García AI, Conde-González CJ, Jiménez-Méndez R, Juárez-Díaz Y, Meda-Monzón E, Torres-Poveda K, Madrid- Marina V. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Sal Púb Méx 2011; 53(Supl. I): S7-S12.

  19. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Sepúlveda J. Prevalencia en México de la infección y el estado portador de la hepatitis B en adultos. Sal Púb Méx 2007; 49(Suppl. 3): S404-S411.

  20. González-Huezo MS, Sánchez-Hernández E, Camacho MC. Prevalencia de marcadores positivos para hepatitis B (Ags- VHB) y hepatitis C (Anti-VHC) en personal de salud del ISSEMYM (Instituto de Seguridad Social del Estado de México y municipios). Rev Gastroenterol Mex 2010; 75(3): 4-11.

  21. Fundación Mexicana para la Salud Hepática. Hepatitis C as a public health problem in Mexico. Sal Púb Méx 2011; 53(Supl. I): S61-S67.

  22. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000; 18(Suppl. 1): S17-S19.

  23. Alvarez-Muñoz T, Bustamante-Calvillo E, Martínez-García C, Moreno-Altamirando L, Guiscafre-Gallardo H, Guiscafre JP, Muñoz O. Seroepidemiology of the hepatitis B and delta in the southeast of Chiapas, Mexico. Arch Invest Med 1989; 20: 189-95.

  24. Roman S, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M, Panduro A. Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. J Med Virol 2010; 82(9): 1527-36.

  25. Juárez-Figueroa LA, Uribe-Salas FJ, Conde-González CJ. Heterogeneous distribution of hepatitis B serological markers in rural areas of Mexico. Sal Púb Méx 2011; 53(Supl. I): S26-S31.

  26. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.

  27. El Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.

  28. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38(Suppl. 1): 90-103.

  29. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007; 31: 1243-8.




2020     |     www.medigraphic.com